Browse the evidence

Hepatic lipid accumulation contributes to insulin resistance through the activation of protein kinase C (PKC) by diacylglycerols (DAGs), but liver lipid can also be a consequence of hyperinsulinemia stimulating lipid synthesis pathways.

Reducing liver fat improves insulin sensitivity, but it's a two-way street: insulin resistance causes liver fat to accumulate, and liver fat worsens insulin resistance. Caloric restriction and carbohydrate reduction can rapidly improve hepatic insulin sensitivity by reducing fatty acid availability and DAG levels.

Men with diabetes mellitus have an approximately 3.5-fold higher prevalence of erectile dysfunction compared to men without diabetes, with severity correlating to the duration and complications of the disease.

If you have diabetes, erectile dysfunction is a common medical complication, not just a psychological issue. It is significantly more likely in diabetic men (3.5x higher risk) and often serves as an early warning sign for heart disease. You should discuss this with your doctor not just for sexual health, but as a critical check on your cardiovascular and metabolic status.

In postmenopausal breast cancer survivors, higher adiposity (BMI, body fat mass, waist circumference) is significantly associated with higher circulating levels of estrone, estradiol, testosterone, and free testosterone, and lower levels of sex hormone-binding globulin (SHBG).

For postmenopausal breast cancer survivors, maintaining a healthy body weight is crucial because excess body fat directly increases levels of estrogen and testosterone, which can fuel cancer growth. While you cannot change your genetics, managing body fat through diet and physical activity may help lower these hormone levels, potentially improving your prognosis. Focus on overall fat reduction rather than just waist size, as total body fat mass is the key driver.

Leptin resistance in obesity is primarily driven by impaired transport of leptin across the blood-brain barrier and intracellular signaling defects (specifically JAK2-STAT3 pathway inhibition by SOCS3 and PTP1B), rather than leptin deficiency.

If you are obese, your body likely produces plenty of leptin, but your brain is ignoring it. This is not because you lack the hormone, but because of biological 'noise' (inflammation, transport issues) blocking the signal. Simply taking leptin supplements is ineffective because the resistance mechanism prevents the hormone from acting on the brain. Focus on reducing the factors that cause this resistance, such as inflammation and high blood-brain barrier permeability issues, rather than seeking leptin replacement.

High serum leptin levels (>25-30 ng/mL) saturate the blood-brain barrier transport system, preventing leptin from entering the brain and thereby contributing to leptin resistance.

In obesity, the body produces so much leptin that it clogs the 'door' (blood-brain barrier) through which the hormone enters the brain. This saturation point means the brain stops receiving the 'full' signal, perpetuating hunger and weight gain. Reducing body fat may help lower leptin levels, potentially restoring the efficiency of this transport system.

Hypothalamic inflammation and endoplasmic reticulum stress are key drivers of leptin resistance, mediated by inflammatory cytokines like IL-6 and TNF-alpha induced by high-fat diets.

High-fat diets trigger inflammation in fat and liver tissue, which releases cytokines (IL-6, TNF-alpha) that disrupt leptin signaling in the brain. Managing inflammation through diet quality (reducing high-fat intake) may help restore leptin sensitivity.

GLP-1 receptor agonists that reduce receptor internalization and beta-arrestin recruitment produce greater sustained insulin secretion and glycemic benefits without increasing nausea side effects compared to standard FDA-approved GLP-1 mimetics.

Current GLP-1 drugs often cause nausea because they trigger strong receptor internalization and beta-arrestin signaling. Research suggests that 'biased' agonists, which keep the receptor on the cell surface longer and avoid beta-arrestin, may provide better blood sugar control with fewer stomach side effects. While these specific compounds are not yet FDA-approved, the mechanism highlights why tolerability varies between different GLP-1 medications.

Vertical sleeve gastrectomy (VSG) and Roux-en-Y gastric bypass (RYGB) produce superior, durable weight loss and metabolic improvements compared to adjustable gastric banding (AGB), primarily through physiological mechanisms rather than simple mechanical restriction.

If you are considering bariatric surgery, understand that 'restrictive' procedures like gastric banding are likely to fail long-term compared to sleeve gastrectomy or gastric bypass. The success of VSG and RYGB comes from hormonal and neural changes, not just a smaller stomach. Choose the procedure based on physiological outcomes, not just surgical simplicity.

In obese and insulin-resistant individuals, adipose tissue exhibits a structural remodeling characterized by decreased capillary density, increased large vessel formation, reduced elastin, and increased Collagen V deposition around large vessels, which collectively inhibit angiogenesis and promote tissue stiffness.

This research highlights that obesity involves complex structural changes in fat tissue, specifically a shift toward stiffer tissue with fewer capillaries and more large vessels. While this paper does not prescribe a specific exercise or diet, it underscores that metabolic health is closely tied to tissue structure. Managing insulin sensitivity through lifestyle interventions may help mitigate these structural changes, though the paper focuses on describing the pathology rather than offering a treatment protocol.

Metformin use significantly alters gut microbiota composition and contributes to its beneficial effects on glucose homeostasis, acting as a strong confounder in metagenomic studies of T2DM.

If you take Metformin for diabetes, your gut bacteria are likely different from non-users. This is a known effect of the drug and may contribute to its benefits. Do not stop taking prescribed medication to 'fix' your microbiota naturally without consulting your doctor.

PLIN2 and PLIN3 regulate lipid droplet hydrolysis in non-adipose tissues but are less effective barriers against lipases than PLIN1, and do not compensate for PLIN1 loss in white adipose tissue.

While PLIN1 is the main protector of fat in fat cells, other proteins (PLIN2/3) handle fat storage in other organs like the liver and muscle. These other proteins are less strict barriers, allowing for more flexible fat usage in tissues that need energy, such as heart and muscle.

Activation of the AMPK pathway inhibits hepatic glucose production, thereby lowering blood glucose levels in type 2 diabetes.

AMPK activation helps lower blood sugar by stopping the liver from producing too much glucose.

Pharmacological agents including statins, PPAR-gamma agonists, ARBs, and incretin-based therapies (sitagliptin, exenatide) can modulate TLR2/4 expression and reduce downstream inflammatory cytokines.

If you are on medications for cholesterol, blood pressure, or diabetes, some of these drugs may also help reduce inflammation by targeting TLRs. Consult your doctor about these effects.

The hormone ghrelin activates AMPK in the hypothalamus to increase appetite and food intake, whereas leptin and insulin inhibit AMPK to decrease appetite.

Hunger hormones like ghrelin turn on your brain's energy sensor (AMPK) to make you eat, while satiety hormones like leptin turn it off. This balance controls your appetite.

Adiponectin activates AMPK to promote fat oxidation and energy expenditure, while also increasing appetite via hypothalamic AMPK activation.

Adiponectin, a hormone from fat cells, helps burn fat in your muscles and liver. Interestingly, it may also signal your brain to eat, mimicking hunger hormones.

Loss-of-function mutations in the Melanocortin-4 Receptor (MC4R) gene cause obesity with variable, age-dependent penetrance, where the likelihood of developing obesity increases significantly with age and across generations due to environmental factors.

If you have a known MC4R loss-of-function mutation, you cannot rely on 'willpower' or educational advantages to prevent obesity. Your risk increases with age and exposure to modern food environments. You must proactively manage your environment (food access, activity levels) starting from childhood and continuing into adulthood, as the genetic risk is not static but accumulates over time.

Aging adipose tissue undergoes early structural and functional decline, characterized by visceral fat redistribution, loss of brown/beige fat, and accumulation of senescent cells, which drives systemic metabolic dysfunction and accelerates aging.

Your fat cells are not just storage; they are active organs that signal your body's health status. As you age, these signals can become harmful, leading to inflammation and metabolic issues. Maintaining healthy adipose tissue through balanced nutrition and activity is crucial for slowing down age-related decline.

Young men with high-normal blood pressure exhibit lower serum adiponectin, smaller LDL particle size, and higher resting heart rate compared to those with optimal blood pressure, independent of BMI.

If your blood pressure is in the 'high-normal' range (e.g., 130-139/85-89 mmHg), do not assume you are metabolically healthy. This state is associated with lower levels of protective adiponectin, less favorable LDL particle size, and higher resting heart rate compared to optimal blood pressure. Prioritize lifestyle interventions to improve insulin sensitivity and lower resting heart rate to mitigate the risk of progressing to type 2 diabetes and cardiovascular disease.

Intermittent administration of the senolytic drug combination dasatinib and quercetin (D&Q) reduces senescence and inflammation in adipose tissue, leading to improved systemic metabolic function (fasting glucose, glucose tolerance, and lipid profiles) in old age.

For older adults, intermittent treatment with dasatinib and quercetin may improve metabolic health by clearing senescent cells from fat tissue, reducing inflammation, and improving glucose tolerance. This suggests that targeting cellular aging could be a viable strategy for managing age-related metabolic decline.

Fructose consumption promotes disease progression from simple steatosis to nonalcoholic steatohepatitis (NASH) by inducing oxidative stress, endoplasmic reticulum (ER) stress, and inflammation via mechanisms including uric acid production and methylglyoxal accumulation.

If you have fatty liver, reducing fructose is crucial not just for fat loss but to stop the inflammation and stress that turn simple fat accumulation into serious liver disease (NASH).

Chronic systemic inflammation drives skeletal muscle atrophy by directly activating pro-catabolic signaling pathways (NF-κB, JAK/STAT, p38MAPK) that increase protein degradation via UPS/ALP and inhibit protein synthesis via IGF-1/Akt/mTOR suppression.

If you are experiencing muscle loss alongside a chronic inflammatory condition (like autoimmune disease, diabetes, or chronic infection), standard resistance training and high protein intake may be insufficient on their own. Medical management of the underlying inflammation is critical to stop the biological signals that actively break down muscle tissue.

Inflammation indirectly causes muscle atrophy by dysregulating the Hypothalamic-Pituitary-Adrenal (HPA) axis, leading to excessive glucocorticoid release, which further inhibits muscle protein synthesis and promotes proteolysis.

Managing stress and underlying inflammation is crucial because chronic stress and inflammation can trigger hormonal responses (cortisol) that actively break down muscle. Medical interventions that stabilize the HPA axis or reduce inflammatory cytokines may help preserve muscle mass.

Myostatin (MSTN) levels are increased by inflammatory factors (TNF-α, IL-6) and act as a negative regulator of muscle mass by activating the Smad2/3 pathway, which upregulates E3 ubiquitin ligases (MuRF1, Atrogin-1) and inhibits satellite cell recruitment.

High levels of inflammatory cytokines can increase Myostatin, a protein that naturally limits muscle growth. In chronic disease, this system is overactive, contributing to muscle loss. Therapies targeting Myostatin or its receptors are being investigated to counteract this loss.

Obesity and type 2 diabetes are characterized by impaired insulin-stimulated PI3K activity and downstream signaling (specifically AS160 phosphorylation and PKCλ/ζ activation) in skeletal muscle, leading to defective GLUT4 translocation and insulin resistance.

In obesity and type 2 diabetes, your muscles' ability to respond to insulin is blunted because the internal signaling chain (PI3K, AS160, PKC) is disrupted, preventing glucose transporters from moving to the cell surface. This is a signaling defect, not necessarily a lack of transporters. Weight loss and specific medications (like TZDs) can help restore this signaling.